Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 243

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Inosine to Increase Serum and Cerebrospinal Fluid Urate in Parkinson Disease: A Randomized Clinical Trial

Open access
Schwarzschild, Michael A., Ascherio, Alberto, Beal, M. Flint, Cudkowicz, Merit E., Curhan, Gary C., Hare, Joshua M., Hooper, D. Craig, Kieburtz, Karl D., Macklin, Eric A., Oakes, David, Rudolph, Alice, Shoulson, Ira, Tennis, Marsha K., Espay, Alberto J., Gartner, Maureen, Hung, Albert, Bwala, Grace, Lenehan, Richard, Encarnacion, Elmyra, Ainslie, Melissa, Castillo, Richard, Togasaki, Daniel, Barles, Gina, Friedman, Joseph H., Niles, Lisa, Carter, Julie H., Murray, Megan, Goetz, Christopher G., Jaglin, Jeana, Ahmed, Anwar, Russell, David S., Cotto, Candace, Goudreau, John L., Russell, Doozie, Parashos, Sotirios Andreas, Ede, Patricia, Saint-Hilaire, Marie H., Thomas, Cathi-Ann, James, Raymond, Stacy, Mark A., Johnson, Julia, Gauger, Lisa, Antonelle de Marcaida, J., Thurlow, Sheila, Isaacson, Stuart H., Carvajal, Lisbeth, Rao, Jayaraman, Cook, Maureen, Hope-Porche, Charlise, McClurg, Lauren, Grasso, Daniela L., Logan, Robert, Orme, Constance, Ross, Tori, Brocht, Alicia F. D., Constantinescu, Radu, Sharma, Saloni, Venuto, Charles, Weber, Joseph, Eaton, Ken · 2014 · JAMA Neurology

Abstract

IMPORTANCE: Convergent biological, epidemiological, and clinical data identified urate elevation as a candidate strategy for slowing disability progression in Parkinson disease (PD). OBJECTIVE: To determine the safety, tolerability, and urate-elevating capability of the urate precursor inosine in early PD and to assess its suitability and potential design features for a disease-modification trial. DESIGN, SETTING, AND PARTICIPANTS: The Safety of Urate Elevation in PD (SURE-PD) study, a randomized, double-blind, placebo-controlled, dose-ranging trial of inosine, enrolled participants from 2009 to 2011 and followed them for up to 25 months at outpatient visits to 17 credentialed clinical study sites of the Parkinson Study Group across the United States. Seventy-five consenting adults (mean age, 62 years; 55% women) with early PD not yet requiring symptomatic treatment and a serum urate concentration less than 6 mg/dL (the approximate population median) were enrolled. INTERVENTIONS: Participants were randomized to 1 of 3 treatment arms: placebo or inosine titrated to produce mild (6.1-7.0 mg/dL) or moderate (7.1-8.0 mg/dL) serum urate elevation using 500-mg capsules taken orally up to 2 capsules 3 times per day. They were followed for up to 24 months (median, 18 months) while receiving the study drug plus 1 washout month. MAIN OUTCOMES AND MEASURES: The prespecified primary outcomes were absence of unacceptable serious adverse events (safety), continued treatment without adverse event requiring dose reduction (tolerability), and elevation of urate assessed serially in serum and once (at 3 months) in cerebrospinal fluid. RESULTS Serious adverse events (17), including infrequent cardiovascular events, occurred at the same or lower rates in the inosine groups relative to placebo. No participant developed gout and 3 receiving inosine developed symptomatic urolithiasis. Treatment was tolerated by 95% of participants at 6 months, and no participant withdrew because of an adverse event. Serum urate rose by 2.3 and 3.0 mg/dL in the 2 inosine groups (P < .001 for each) vs placebo, and cerebrospinal fluid urate level was greater in both inosine groups (P = .006 and <.001, respectively). Secondary analyses demonstrated nonfutility of inosine treatment for slowing disability. CONCLUSIONS AND RELEVANCE: Inosine was generally safe, tolerable, and effective in raising serum and cerebrospinal fluid urate levels in early PD. The findings support advancing to more definitive development of inosine as a potential disease-modifying therapy for PD. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00833690.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamaneurol.2013.5528

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 243

Metadata

Authors
Schwarzschild, M. A., Ascherio, A., Beal, M. F., Cudkowicz, M. E., Curhan, G. C., Hare, J. M., Hooper, D. C., Kieburtz, K. D., Macklin, E. A., Oakes, D., Rudolph, A., Shoulson, I., Tennis, M. K., Espay, A. J., Gartner, M., Hung, A., Bwala, G., Lenehan, R., Encarnacion, E., Ainslie, M., Castillo, R., Togasaki, D., Barles, G., Friedman, J. H., Niles, L., Carter, J. H., Murray, M., Goetz, C. G., Jaglin, J., Ahmed, A., Russell, D. S., Cotto, C., Goudreau, J. L., Russell, D., Parashos, S. A., Ede, P., Saint-Hilaire, M. H., Thomas, C.-A., James, R., Stacy, M. A., Johnson, J., Gauger, L., Antonelle de Marcaida, J., Thurlow, S., Isaacson, S. H., Carvajal, L., Rao, J., Cook, M., Hope-Porche, C., McClurg, L., Grasso, D. L., Logan, R., Orme, C., Ross, T., Brocht, A. F. D., Constantinescu, R., Sharma, S., Venuto, C., Weber, J., & Eaton, K.
Venue
JAMA Neurology
Published
2014-02-01
Volume
71
Issue
2
Pages
141
ISSN
2168-6149 (ISSN-L)
OpenAlex
W2083757931
Cited by
243
References
2
FWCI
16.10
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Inosine to Increase Serum and Cerebrospinal Fluid Urate in Parkinson Disease: A Randomized Clinical Trial. https://app.cochat.ai/papers/10.1001/jamaneurol.2013.5528
The paper
Schwarzschild, M. A., Ascherio, A., Beal, M. F., Cudkowicz, M. E., Curhan, G. C., Hare, J. M., Hooper, D. C., Kieburtz, K. D., Macklin, E. A., Oakes, D., Rudolph, A., Shoulson, I., Tennis, M. K., Espay, A. J., Gartner, M., Hung, A., Bwala, G., Lenehan, R., Encarnacion, E., . . . Eaton, K. (2014). Inosine to Increase Serum and Cerebrospinal Fluid Urate in Parkinson Disease: A Randomized Clinical Trial. JAMA Neurology. https://doi.org/10.1001/jamaneurol.2013.5528

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.